NO20032542D0 - Attenuated anti-CD28 antibodies and their use - Google Patents

Attenuated anti-CD28 antibodies and their use

Info

Publication number
NO20032542D0
NO20032542D0 NO20032542A NO20032542A NO20032542D0 NO 20032542 D0 NO20032542 D0 NO 20032542D0 NO 20032542 A NO20032542 A NO 20032542A NO 20032542 A NO20032542 A NO 20032542A NO 20032542 D0 NO20032542 D0 NO 20032542D0
Authority
NO
Norway
Prior art keywords
antibodies
attenuated anti
attenuated
Prior art date
Application number
NO20032542A
Other languages
Norwegian (no)
Other versions
NO20032542L (en
Inventor
J Yun Tso
Paul Hinton
Maximiliano Vasquez
Kouichi Tamura
Yasuyuki Higashi
Nobuo Seki
Hirotsugu Ueda
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20032542D0 publication Critical patent/NO20032542D0/en
Publication of NO20032542L publication Critical patent/NO20032542L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
NO20032542A 2000-12-14 2003-06-05 Attenuated anti-CD28 antibodies and their use NO20032542L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (2)

Publication Number Publication Date
NO20032542D0 true NO20032542D0 (en) 2003-06-05
NO20032542L NO20032542L (en) 2003-08-07

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20032542A NO20032542L (en) 2000-12-14 2003-06-05 Attenuated anti-CD28 antibodies and their use

Country Status (18)

Country Link
EP (1) EP1341553A4 (en)
JP (1) JP2004515243A (en)
KR (1) KR20040020866A (en)
CN (1) CN1272345C (en)
AR (1) AR031924A1 (en)
AU (2) AU2608602A (en)
BR (1) BR0116686A (en)
CA (1) CA2432736A1 (en)
CZ (1) CZ20031909A3 (en)
HU (1) HUP0400697A3 (en)
IL (1) IL156262A0 (en)
MX (1) MXPA03005327A (en)
NO (1) NO20032542L (en)
NZ (1) NZ526569A (en)
PL (1) PL363239A1 (en)
RU (1) RU2261723C2 (en)
WO (1) WO2002047721A1 (en)
ZA (1) ZA200305384B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US7531168B2 (en) 2001-02-16 2009-05-12 Genetics Institute Llc Method for downmodulating immune response in type I diabetes
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
FR2951176A1 (en) * 2009-10-09 2011-04-15 Tcl Pharma MONOVALENT LIGANDS OF THE HUMAN CD28 RECEPTOR
US8785604B2 (en) * 2010-02-18 2014-07-22 Effimune Anti-CD28 humanized antibodies
EP3528787A4 (en) 2016-10-21 2020-05-06 Amgen Inc. Pharmaceutical formulations and methods of making the same
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
CA3130348A1 (en) * 2019-03-14 2020-09-17 Motti HAKIM A method for immunosuppression
MA55805A (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc METHODS OF MODULATING IMMUNE ACTIVITY
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (en) 2020-06-29 2023-05-09 旗舰创业创新五公司 Virus engineered to promote saenox delivery and use thereof in treating cancer
KR102607909B1 (en) 2020-08-19 2023-12-01 젠코어 인코포레이티드 Anti-CD28 composition
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28

Also Published As

Publication number Publication date
ZA200305384B (en) 2004-10-11
EP1341553A1 (en) 2003-09-10
BR0116686A (en) 2003-12-30
WO2002047721A1 (en) 2002-06-20
IL156262A0 (en) 2004-01-04
CZ20031909A3 (en) 2003-11-12
PL363239A1 (en) 2004-11-15
RU2003121231A (en) 2005-02-10
CA2432736A1 (en) 2002-06-20
RU2261723C2 (en) 2005-10-10
AR031924A1 (en) 2003-10-08
HUP0400697A2 (en) 2004-06-28
EP1341553A4 (en) 2004-07-28
JP2004515243A (en) 2004-05-27
CN1272345C (en) 2006-08-30
NZ526569A (en) 2005-07-29
MXPA03005327A (en) 2004-12-03
AU2608602A (en) 2002-06-24
CN1489473A (en) 2004-04-14
NO20032542L (en) 2003-08-07
AU2002226086B2 (en) 2005-08-25
HUP0400697A3 (en) 2007-05-02
AU2002226086C1 (en) 2006-03-09
KR20040020866A (en) 2004-03-09

Similar Documents

Publication Publication Date Title
CY2019029I1 (en) ANTI-TNF ANTIBODIES, COMPOSITIONS, METHODS AND USES
DK1390389T3 (en) Crypto-blocking antibodies and uses thereof
NO20034405D0 (en) Anti-cheese pontine antibody and its use
IS6779A (en) Human antibody against LT-beta-R
DK1691837T3 (en) IP-10 antibodies and their use
DK1417175T3 (en) SUBSTITUTED DIHYDRO-3-HALO-1H-PYRAZOL-5-CARBOXYLATES AND PREPARATION AND USE THEREOF
DK1122244T3 (en) Uracil compounds and their use
NO20030614L (en) Anti-IL-12 Antibodies, Compositions, Methods and Uses
IS7041A (en) 5-HT receptors and their use
NO20021449D0 (en) Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
TWI316088B (en) Anti-tnf alpha antibodies and their uses
DK1711207T3 (en) Interferon-alpha antibodies and their use
NO20033418L (en) Immune regulatory antibodies and their use
IS6411A (en) Kaspasa inhibits and their use
NO20033456L (en) Modified and stabilized GDF propeptides and their use
DK1278763T3 (en) 3-Nitrogen-6,7-dioxygen steroids and related applications
DK1339292T3 (en) Composition and method
NO20032542D0 (en) Attenuated anti-CD28 antibodies and their use
NO20034159D0 (en) The estrogen-gestagen combination preparation and its use
DK1322597T3 (en) Process and intermediate
DK1140952T3 (en) Phosphorus-organic compounds and their use
FI20000432A (en) reducer
NO20032821D0 (en) Sea-trosy and related practices
DK1317478T3 (en) The distinction between GnRH-I and GnRH-II
IS6570A (en) Pressure-reducing agents and use

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

FC2A Withdrawal, rejection or dismissal of laid open patent application